poisar

Stocks · News reference

These Analysts Boost Their Forecasts On Nordson After Q3 Earnings

Avi Kapoor

Nordson Corp (NASDAQ: NDSN) reported strong Q3 results and increased its guidance for FY2026. Analysts raised price targets. Stock rose 0.3% in pre-market.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NDSN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks.Com

    Nordson (NDSN) Down 6.9% Since Last Earnings Report: Can It Rebound?

    Nordson reported strong Q3 fiscal 2026 earnings with adjusted EPS of $3.25 (beating estimates by 5.2%) and revenues of $817.67 million (up 10.3%), driven by broad organic growth across all three segments and record sales. Despite the solid results, the stock has declined 6.9% since the earnings report. The company raised full-year guidance and maintains a Zacks Rank #2 (Buy) rating with upward estimate revisions, suggesting potential for recovery.

    NDSNDNOW
  2. Researchandmarkets.Com

    Syringe Filling Machine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031), Syringe Filling Machine Market to Reach USD 2.99 Billion

    The global syringe filling machine market is projected to grow from USD 2.09 billion in 2026 to USD 2.99 billion by 2031 at a 7.41% CAGR. Growth is driven by rising demand for prefilled syringes, automated fill-finish lines for biologics, and regulatory focus on aseptic accuracy. Automated systems dominate with 63.92% market share, while servo-driven piston technology leads at 44.05%. Asia-Pacific emerges as the fastest-growing region at 10.72% CAGR, driven by biologics capacity expansion.

    BDXNDSNWXXWY
  3. Na

    Nordson Rewards Investors With 15% Dividend Hike on Strong Cash Flow

    Nordson Corporation announced a 15% increase in its quarterly dividend to 94 cents per share, payable October 2, 2026. The company has raised its dividend for 63 consecutive years with a five-year CAGR of 13.7%, demonstrating strong capital allocation through $137.4 million in dividend payments and $158.8 million in share repurchases over nine months. Despite solid performance in its Medical and Industrial segments, the company faces headwinds from high debt levels and currency exposure.

    NDSNGNRCCRHLIO